Manages manifestations of psychotic disorders. ANDA 212144, held by Glenmark Pharms Ltd. Chlorpromazine Hydrochloride.
As of Nov 16, 2026, ANDA 212144 (Chlorpromazine Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 23, 2021, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 23, 2021 | Original application | Approved |
| Chlorpromazine Hydrochloride10MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride25MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride50MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride100MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride200MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters